World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Leaner Pfizer Expects Clean Bill of Health
Keywords:
Jakab says Pfizer has managed the transition to a generic version of Lipitor and loss of revenues from the blockbuster drug in a well planned manner. The branded version of Lipitor still has a 32% market share according to IMS. An approved generic version of Lipitor sold by Watson Pharmaceuticals has a 27% market share. As a result the shock of losing Lipitor revenues has been cushioned to some extent. In 2008 Lipitor comprised 26% of Pfizer sales, in 2011 this has about 14%. This was partly achieved by acquiring Wyeth in 2009. Pfizer has returned $12 billion to shareholders in dividends and share buybacks in the year ending September.
Pfizer strategy and restructuring- 2010-2015
04/08/2009
Grouped Articles
Pfizer to Pursue Bid for AstraZeneca
Wall Street Journal 04/28/2014
In Drug Mergers, There's One Sure Bet: The Layoffs
Wall Street Journal 04/30/2014
Pfizer Outlines Post-Wyeth R&D Structure
Wall Street Journal 04/08/2009
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Spurned by AstraZeneca, Pfizer Walks Away
Wall Street Journal 05/27/2014
Pfizer to Buy Hospira for $16 Billion
Wall Street Journal 02/06/2015
Pfizer and Generic Lipitor
11/02/2011
Grouped Articles
Forget Generics, Pfizer Has Plenty of 'Lipitor for You'
Wall Street Journal 11/02/2011
Wall Street Journal 11/22/2011
Generic Lipitor Sets Off an Aggressive Push by Pfizer
New York Times 11/29/2011
Leaner Pfizer Expects Clean Bill of Health
Wall Street Journal 01/31/2012
Pfizer Profit Declines 19% After Loss of Lipitor Patent
New York Times 05/01/2012
The Practical Healing Measures at Pfizer
Wall Street Journal 07/31/2012
Pfizer management.
07/31/2006
Grouped Articles
For Drug Deals, Small Is Beautiful
Wall Street Journal 03/12/2009
In Drug Mergers, There's One Sure Bet: The Layoffs
Wall Street Journal 04/30/2014
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Spurned by AstraZeneca, Pfizer Walks Away
Wall Street Journal 05/27/2014
Pfizer Bets $15 Billion on New Class of Generic Drugs
New York Times 02/05/2015
Why Allergan Is a Cure for What Ails Pfizer
Wall Street Journal 10/30/2015
Pfizer and an over the counter version of Lipitor
08/04/2011
Grouped Articles
Pfizer Looks At Lipitor Over Counter
Wall Street Journal 08/04/2011
Wall Street Journal 11/22/2011
Generic Lipitor Sets Off an Aggressive Push by Pfizer
New York Times 11/29/2011
Leaner Pfizer Expects Clean Bill of Health
Wall Street Journal 01/31/2012
Pfizer Profit Declines 19% After Loss of Lipitor Patent
New York Times 05/01/2012
Pfizer's Cost-Cuts Offset Loss of Lipitor
Wall Street Journal 08/01/2012
Pfizer performance 2010-2015
04/19/2011
Grouped Articles
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Spurned by AstraZeneca, Pfizer Walks Away
Wall Street Journal 05/27/2014
Pfizer to Buy Hospira for $16 Billion
Wall Street Journal 02/06/2015
Pfizer Bets $15 Billion on New Class of Generic Drugs
New York Times 02/05/2015
Why Allergan Is a Cure for What Ails Pfizer
Wall Street Journal 10/30/2015
Wall Street Journal 04/19/2011
Pfizer restructuring.
07/31/2006
Grouped Articles
Pfizer to Pursue Bid for AstraZeneca
Wall Street Journal 04/28/2014
In Drug Mergers, There's One Sure Bet: The Layoffs
Wall Street Journal 04/30/2014
Pfizer Outlines Post-Wyeth R&D Structure
Wall Street Journal 04/08/2009
Pfizer's New Chief Faces Several Challenges
Wall Street Journal 07/31/2006
As Drug Industry Struggles, Chemists Face Layoff Wave
Wall Street Journal 12/11/2007
Can Pfizer Deliver a New Prescription?
Wall Street Journal 03/04/2008
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
